Phosphate control in reducing FGF23 levels in hemodialysis patients

被引:30
|
作者
Rodelo-Haad, Cristian [1 ,2 ,3 ]
Rodriguez-Ortiz, Maria E. [1 ,3 ]
Martin-Malo, Alejandro [1 ,2 ,3 ]
Victoria Pendon-Ruiz de Mier, M. [1 ,2 ,3 ]
Luisa Aguera, M. [1 ,2 ,3 ]
Munoz-Castaneda, Juan R. [1 ,2 ,3 ]
Soriano, Sagrario [1 ,2 ,3 ]
Caravaca, Francisco [4 ]
Antonia Alvarez-Lara, M. [1 ,2 ,3 ]
Felsenfeld, Arnold [5 ,6 ]
Aljama, Pedro [1 ,2 ,3 ]
Rodrigue, Mariano [1 ,2 ,3 ]
机构
[1] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Reina Sofia Univ Hosp, Cordoba, Spain
[2] Reina Sofia Univ Hosp, Nephrol Serv, Cordoba, Spain
[3] RETICs REDinREN Natl Inst Hlth Carlos III, Madrid, Spain
[4] Infanta Cristina Hosp, Nephrol Serv, Badajoz, Spain
[5] UCLA, Wadsworth VA, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源
PLOS ONE | 2018年 / 13卷 / 08期
关键词
GROWTH-FACTOR; 23; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; CKD-MBD; SECONDARY HYPERPARATHYROIDISM; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; DIALYSIS PATIENTS; LANTHANUM CARBONATE; PARATHYROID-HORMONE;
D O I
10.1371/journal.pone.0201537
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. Material and methods The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. Results During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate <4.5 mg/dl. In these 12 patients, iFGF23 decreased to less than half whereas cFGF23 did not reduce significantly. In patients with serum phosphate >4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. Conclusions The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency
    Iguchi, Akira
    Kazama, Junichiro J.
    Yamamoto, Suguru
    Yoshita, Kazuhiro
    Watanabe, Yasuo
    Iino, Noriaki
    Narita, Ichiei
    NEPHRON, 2015, 131 (03) : 161 - 166
  • [2] FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction
    Nielsen, Ture Lange
    Plesner, Louis Lind
    Warming, Peder Emil
    Mortensen, Ole Hartvig
    Iversen, Kasper Karmark
    Heaf, James Goya
    NEFROLOGIA, 2019, 39 (03): : 258 - 268
  • [3] FGF23 and Phosphate-Cardiovascular Toxins in CKD
    Vogt, Isabel
    Haffner, Dieter
    Leifheit-Nestler, Maren
    TOXINS, 2019, 11 (11)
  • [4] FGF23, Biomarker or Target?
    Rodelo-Haad, Cristian
    Santamaria, Rafael
    Munoz-Castaneda, Juan R.
    Victoria Pendon-Ruiz de Mier, M.
    Martin-Malo, Alejandro
    Rodriguez, Mariano
    TOXINS, 2019, 11 (03):
  • [5] FGF23 and Nutritional Metabolism
    Pool, Lindsay R.
    Wolf, Myles
    ANNUAL REVIEW OF NUTRITION, VOL 37, 2017, 37 : 247 - 268
  • [6] Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23 Levels in CKD
    Isakova, Tamara
    Barchi-Chung, Allison
    Enfield, Gwen
    Smith, Kelsey
    Vargas, Gabriella
    Houston, Jessica
    Xie, Huiliang
    Wahl, Patricia
    Schiavenato, Eva
    Dosch, Austin
    Gutierrez, Orlando M.
    Diego, Jorge
    Lenz, Oliver
    Contreras, Gabriel
    Mendez, Armando
    Weiner, Rory B.
    Wolf, Myles
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (06): : 1009 - 1018
  • [7] Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD
    Zhang, L-N
    Yang, G.
    Cheng, C.
    Shen, C.
    Cui, Y-Y
    Zhang, J.
    Zhang, J-J
    Shen, Z-X
    Zeng, M.
    Ge, Y-F
    Sun, B.
    Yu, X-B
    Ouyang, C.
    Zhang, B.
    Mao, H-J
    Liu, J.
    Xing, C-Y
    Zha, X-M
    Wang, N-N
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 395 - 405
  • [8] FGF23 at the crossroads of phosphate, iron economy and erythropoiesis
    Edmonston, Daniel
    Wolf, Myles
    NATURE REVIEWS NEPHROLOGY, 2020, 16 (01) : 7 - 19
  • [9] Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients
    Egli-Spichtig, Daniela
    Hamid, Ahmad Kamal
    Arroyo, Eva Maria Pastor
    Ketteler, Markus
    Wiecek, Andrzej
    Rosenkranz, Alexander R.
    Pasch, Andreas
    Lorenz, Horst
    Hellmann, Burkhard
    Karus, Michael
    Ammer, Richard
    Rubio-Aliaga, Isabel
    Wagner, Carsten A.
    CLINICAL KIDNEY JOURNAL, 2023, 16 (10) : 1622 - 1633
  • [10] Single FGF-23 Measurement and Time-Averaged Plasma Phosphate Levels in Hemodialysis Patients
    Seiler, Sarah
    Lucisano, Gaetano
    Ege, Philipp
    Fell, Lisa H.
    Rogacev, Kyrill S.
    Lerner-Graeber, Anne
    Klingele, Matthias
    Ziegler, Matthias
    Fliser, Danilo
    Heine, Gunnar H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (10): : 1764 - 1772